0 81

Cited 4 times in

Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer.

 Bae Ahn, Joong  ;  Ki Ko, Won  ;  Gu Lee, Jun  ;  Yong Shim, Kwang  ;  Cheul Jeung, Hei  ;  Oh Park, Joon  ;  Choon Yoo, Nae  ;  Soo Kim, Byung  ;  Kyu Kim, Se  ;  Kyu Kim, Sung  ;  Hang Kim, Joo 
 American Journal of Clinical Oncology, Vol.23(6) : 622-628, 2000 
Journal Title
 American Journal of Clinical Oncology 
Issue Date
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Carcinoma, Non-Small-Cell Lung/drug therapy* ; Cisplatin/administration & dosage ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Ifosfamide/administration & dosage ; Lung Neoplasms/drug therapy* ; Male ; Middle Aged ; Survival Analysis ; Vinblastine/administration & dosage ; Vinblastine/analogs & derivatives*
Vinorelbine ; Cisplatin ; Ifosfamide ; Non-small- cell lung cancer ; Summation dose intensity
Cisplatin-based chemotherapy is being tried in the treatment of nonoperable cases of non-small-cell lung cancer (NSCLC). However, the prognosis is unfavorable and to improve survival, clinical studies using various combinations of a variety of drugs as well as experimental material are in progress. We compared the efficacy and toxicities of combination chemotherapy using different doses of vinorelbine and ifosfamide with a constant dose of cisplatin in this study. Patients diagnosed with inoperable stage III or IV NSCLC between June 1997 and December 1998 were included. Cisplatin was administered at a constant dose of 80 mg/m2 on day 5, whereas vinorelbine on days 1 and 5 and ifosfamide on day 5 were administered in one of two different doses. In arm A, vinorelbine 25 mg/m2 and ifosfamide 3.0 g/m2 were administered. In arm B, vinorelbine 20 mg/m2 and ifosfamide 2.5 g/m2 were administered. Also, we reviewed for phase II and III studies that test 1) cisplatin, 2) vinorelbine monotherapy, and 3) vinorelbine/cisplatin/ifosfamide combination chemotherapy for stage IIIb-IV non-SCLC. Summation dose intensity (SDI) was calculated in each published and current study. Twenty patients in arm A and 35 patients in arm B were available for evaluation. There was no difference in patient activity, pathologic diagnosis, and differentiation or stage between the two arms. The median number of cycles was four in both arms. The response rate was 50% in arm A and 30% in arm B. The median survival times for arm A and B were 40 and 42 weeks, respectively, whereas the SDI was 1.94 and 1.7, respectively. More than grade III leukopenia was observed in 28.9% in arm A, which is more frequent than the 17.2% in arm B. There was a significant correlation between the SDIs and response rates and median survival (r2 = 0.629, p = 0.001; r2 = 0.453, p = 0.001, respectively). Although the follow-up period is relatively short, the survival time was similar in both arms. Because a high response rate may not be followed by a high survival time in combination chemotherapy of NSCLC, further studies on the appropriate dose of individual agents with regard to the relationship between response rate, severity, and incidence of toxicities and survival rate should be carried out.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Joo Hang(김주항)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.